CAM
SVA

ClariVest Asset Management’s Sinovac Biotech, Ltd SVA Stock Holding History

ClariVest Asset Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,517
Closed -$83K – 772
2017
Q1 		$83K Buy
+14,517
New +$84K ﹤0.01% 573
2015
Q1 		– Sell
-19,726
Closed -$103K – 688
2014
Q4 		$103K Hold
19,726
– – ﹤0.01% 412
2014
Q3 		$95K Sell
19,726
-8,722
-31% -$46.8K ﹤0.01% 439
2014
Q2 		$160K Buy
28,448
+3,248
+13% +$19.7K 0.01% 384
2014
Q1 		$181K Buy
+25,200
New +$167K 0.01% 360

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ClariVest Asset Management's SVA Position: Q2 2017 in Review

ClariVest Asset Management sold out of Sinovac Biotech, Ltd (SVA) in Q2 2017, closing a stake of 14,517 shares — an estimated $83K sold.

ClariVest Asset Management first reported a position in SVA in Q1 2014 and held it in 5 quarters. The position peaked at $181K in Q1 2014. 37 funds tracked by Wall St. Rank hold SVA as of Q2 2017.

  • ClariVest Asset Management reported no remaining Sinovac Biotech, Ltd position as of Q2 2017 after selling out during the quarter.
  • ClariVest Asset Management sold 14,517 Sinovac Biotech, Ltd shares in Q2 2017, an estimated $83K.
  • ClariVest Asset Management first reported a position in Sinovac Biotech, Ltd in Q1 2014 and held it in 5 quarters.
  • ClariVest Asset Management's Sinovac Biotech, Ltd position peaked at $181K in Q1 2014.
  • 37 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2017.

Based on ClariVest Asset Management's 13F filing for Q2 2017, filed 2 Aug 2017.